Cite
HARVARD Citation
Querfeld, C. et al. (2021). Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Lancet. 8 (11), pp. e808-e817. [Online].